Tech Company Financing Transactions
Umoja Biopharma Funding Round
On 6/16/2021, Umoja Biopharma received $210 million in Series B funding from Cormorant Asset Management, SoftBank Vision Fund and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
6/16/2021
Transaction Type
Venture Equity
Amount
$210,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1920 Terry Ave.
Seattle, WA 98101
USA
Seattle, WA 98101
USA
Phone
Undisclosed
Website
Email Address
Overview
Umoja is driven by a bold and unified vision to transform cancer treatment and improve quality of life. We are a diverse group of drug development experts, scientists and researchers that are skilled, passionate, persistent, and relentlessly committed to finding a way to break through the current challenges encountered in immuno-oncology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Scharenberg
Chief Financial Officer
Irena Melnikova
Chief Medical Officer
Nushmia Khokhar
Chief Technical Officer
Ryan Crisman
Controller
Kelli Carabello
Vice President
Jacob Garcia
Vice President
Rich Getto
Vice President
Byoung Ryu
VP - Bus. Development
David Fontana
VP - Bus. Development
Timothy Gardner
VP - Operations
Gretchen Torrey
VP - Product Management
Bruce Kerwin
VP - Regulatory Affairs
Helen Kim
VP - Regulatory Affairs
Sagar Patel
Browse more venture capital transactions:
Prev: 6/16/2021: Addepar venture capital transaction
Next: 6/16/2021: IRL venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs